Splash

Investors

We are committed to delivering our strategy and creating value for our shareholders.
Splash
Investors
Latest Results

Latest Results

We’re pleased to announce our latest results.

Download Results

Latest News

Latest Events

13 October 2020Regulatory
Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020

Posters highlight ensifentrine’s potential to provide rapid benefits LONDON and RALEIGH, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will present

23 September 2020Regulatory
Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD

LONDON and RALEIGH, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of its ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”)

21 September 2020Regulatory
Intended Delisting and Cancellation of Ordinary Shares from Trading on AIM

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (“MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN

View all regulatory news
Splash

© Verona Pharma plc 2020. All rights reserved